Új lehetoségek az endokrin orbitopathia kezelé sében

Translated title of the contribution: Novel treatment opportunities in Graves' orbitopathy

Annamária Erdei, Annamária Gazdag, Miklós Bodor, Eszter Berta, Mónika Katkó, Bernadett Ujhelyi, Zita Steiber, Ferenc Gyory, Hilda Urbancsek, Sándor Barna, L. Galuska, V. Endre Nagy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Graves' orbitopathy is the most common extrathyroidal manifestation of Graves' disease. Up to now, curative treatment modalities for the most severe sight-threatening cases have not been developed. Here the authors summarize the treatment protocol of Graves' orbitopathy and review novel therapeutic options. They review the literature on this topic and present their own clinical experience. The authors point out that anti-CD20 antibody could positively influence the clinical course of Graves' orbitopathy. Selenium is efficient in mild cases. Further prospective investigations are warranted.

Original languageHungarian
Pages (from-to)1295-1300
Number of pages6
JournalOrvosi Hetilap
Volume155
Issue number33
DOIs
Publication statusPublished - Aug 1 2014

Fingerprint

Graves Disease
Clinical Protocols
Selenium
Anti-Idiotypic Antibodies
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Erdei, A., Gazdag, A., Bodor, M., Berta, E., Katkó, M., Ujhelyi, B., ... Nagy, V. E. (2014). Új lehetoségek az endokrin orbitopathia kezelé sében. Orvosi Hetilap, 155(33), 1295-1300. https://doi.org/10.1556/OH.2014.29963

Új lehetoségek az endokrin orbitopathia kezelé sében. / Erdei, Annamária; Gazdag, Annamária; Bodor, Miklós; Berta, Eszter; Katkó, Mónika; Ujhelyi, Bernadett; Steiber, Zita; Gyory, Ferenc; Urbancsek, Hilda; Barna, Sándor; Galuska, L.; Nagy, V. Endre.

In: Orvosi Hetilap, Vol. 155, No. 33, 01.08.2014, p. 1295-1300.

Research output: Contribution to journalArticle

Erdei, A, Gazdag, A, Bodor, M, Berta, E, Katkó, M, Ujhelyi, B, Steiber, Z, Gyory, F, Urbancsek, H, Barna, S, Galuska, L & Nagy, VE 2014, 'Új lehetoségek az endokrin orbitopathia kezelé sében', Orvosi Hetilap, vol. 155, no. 33, pp. 1295-1300. https://doi.org/10.1556/OH.2014.29963
Erdei A, Gazdag A, Bodor M, Berta E, Katkó M, Ujhelyi B et al. Új lehetoségek az endokrin orbitopathia kezelé sében. Orvosi Hetilap. 2014 Aug 1;155(33):1295-1300. https://doi.org/10.1556/OH.2014.29963
Erdei, Annamária ; Gazdag, Annamária ; Bodor, Miklós ; Berta, Eszter ; Katkó, Mónika ; Ujhelyi, Bernadett ; Steiber, Zita ; Gyory, Ferenc ; Urbancsek, Hilda ; Barna, Sándor ; Galuska, L. ; Nagy, V. Endre. / Új lehetoségek az endokrin orbitopathia kezelé sében. In: Orvosi Hetilap. 2014 ; Vol. 155, No. 33. pp. 1295-1300.
@article{52e2b360ca4b4b00aeaf4dc4bc227b79,
title = "{\'U}j lehetos{\'e}gek az endokrin orbitopathia kezel{\'e} s{\'e}ben",
abstract = "Graves' orbitopathy is the most common extrathyroidal manifestation of Graves' disease. Up to now, curative treatment modalities for the most severe sight-threatening cases have not been developed. Here the authors summarize the treatment protocol of Graves' orbitopathy and review novel therapeutic options. They review the literature on this topic and present their own clinical experience. The authors point out that anti-CD20 antibody could positively influence the clinical course of Graves' orbitopathy. Selenium is efficient in mild cases. Further prospective investigations are warranted.",
keywords = "biological therapy, biol{\'o}giai ter{\'a}pia, endokrin orbitopathia, Graves' disease, Graves' orbitopathy, Graves-k{\'o}r, selenium, szel{\'e}n",
author = "Annam{\'a}ria Erdei and Annam{\'a}ria Gazdag and Mikl{\'o}s Bodor and Eszter Berta and M{\'o}nika Katk{\'o} and Bernadett Ujhelyi and Zita Steiber and Ferenc Gyory and Hilda Urbancsek and S{\'a}ndor Barna and L. Galuska and Nagy, {V. Endre}",
year = "2014",
month = "8",
day = "1",
doi = "10.1556/OH.2014.29963",
language = "Hungarian",
volume = "155",
pages = "1295--1300",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "33",

}

TY - JOUR

T1 - Új lehetoségek az endokrin orbitopathia kezelé sében

AU - Erdei, Annamária

AU - Gazdag, Annamária

AU - Bodor, Miklós

AU - Berta, Eszter

AU - Katkó, Mónika

AU - Ujhelyi, Bernadett

AU - Steiber, Zita

AU - Gyory, Ferenc

AU - Urbancsek, Hilda

AU - Barna, Sándor

AU - Galuska, L.

AU - Nagy, V. Endre

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Graves' orbitopathy is the most common extrathyroidal manifestation of Graves' disease. Up to now, curative treatment modalities for the most severe sight-threatening cases have not been developed. Here the authors summarize the treatment protocol of Graves' orbitopathy and review novel therapeutic options. They review the literature on this topic and present their own clinical experience. The authors point out that anti-CD20 antibody could positively influence the clinical course of Graves' orbitopathy. Selenium is efficient in mild cases. Further prospective investigations are warranted.

AB - Graves' orbitopathy is the most common extrathyroidal manifestation of Graves' disease. Up to now, curative treatment modalities for the most severe sight-threatening cases have not been developed. Here the authors summarize the treatment protocol of Graves' orbitopathy and review novel therapeutic options. They review the literature on this topic and present their own clinical experience. The authors point out that anti-CD20 antibody could positively influence the clinical course of Graves' orbitopathy. Selenium is efficient in mild cases. Further prospective investigations are warranted.

KW - biological therapy

KW - biológiai terápia

KW - endokrin orbitopathia

KW - Graves' disease

KW - Graves' orbitopathy

KW - Graves-kór

KW - selenium

KW - szelén

UR - http://www.scopus.com/inward/record.url?scp=84905994177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905994177&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29963

DO - 10.1556/OH.2014.29963

M3 - Article

C2 - 25109914

AN - SCOPUS:84905994177

VL - 155

SP - 1295

EP - 1300

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 33

ER -